Collectively, as emerging data have started to uncover its underestimated impacts on drug resistance, there are increasing expectations that encouraging results of preclinical or clinical studies on targeted PDK1 could be achieved in chemoresistant BC cells, or even better. The gene discussed is PDK1; the disease is breast cancer.